{
    "clinical_study": {
        "@rank": "48532", 
        "arm_group": {
            "arm_group_label": "RYGB/SG Diabetic NAFLD", 
            "description": "30 diabetic patients with NAFLD undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) and a low carbohydrates diet before surgery."
        }, 
        "biospec_descr": {
            "textblock": "Whole blood, Liver tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of weight loss rate on liver\n      steatosis, steatohepatitis and fibrosis at different stages before and after bariatric\n      surgery. In addition, the investigators would like to study the effect of low carbohydrate\n      diet given for a month before bariatric surgery on liver steatosis. The investigators also\n      aim to study the short-term effect of bariatric surgery on gastric cholecystokinin levels\n      before and 10 days after the bariatric surgery."
        }, 
        "brief_title": "Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease in Diabetic Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nonalcoholic Fatty Liver Disease (NAFLD).", 
            "Nonalcoholic Steatohepatitis.", 
            "Diabetes."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20\u2264 age \u226480\n\n          -  BMI>35kg/m2\n\n          -  Men and women\n\n          -  Fatty infiltration in liver ultrasonography > 30%\n\n          -  Diagnosed diabetes according to:\n\n               1. HbA1c\u22656.8% or\n\n               2. Fasting plasma glucose (PG) \u2265126mg/dl or\n\n               3. 2 hours PG \u2265 200mg/dl during 75gr Oral glucose tolerance test, or\n\n               4. random PG\u2265200mg/dl and hyperglycemic symptoms)\n\n        Exclusion Criteria:\n\n          -  Alcohol drinking > 140g/week\n\n          -  Presence of hepatitis B or C or HIV\n\n          -  Known liver disease such as:\n\n               1. Wilson's disease\n\n               2. hemochromatosis\n\n               3. \u03b11-antitrypsin deficiency\n\n               4. autoimmune liver disease\n\n               5. primary biliary cirrhosis\n\n               6. primary sclerosing cholangitis)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "30 diabetic patients with NAFLD (diagnosed by ultra sound) undergoing Roux-en-Y gastric\n        bypass (RYGB) or sleeve gastrectomy (SG) at Surgery C department at Sheba Medical Center,\n        Israel."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828528", 
            "org_study_id": "SHEBA-12-0026-ZB-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "RYGB/SG Diabetic NAFLD", 
                "description": "Surgery includes intraoperative Tru-Cut liver biopsy.", 
                "intervention_name": "Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG).", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "RYGB/SG Diabetic NAFLD", 
                "description": "Low carbohydrates diet, starting 3 weeks before surgery, providing daily amount of: 60g Carbohydrates, 1400 Kilo-Calories and 130g protein.", 
                "intervention_name": "Low carbohydrate diet", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nonalcoholic fatty liver disease", 
            "Nonalcoholic steatohepatitis", 
            "Obesity", 
            "Bariatric surgery", 
            "Weight loss"
        ], 
        "lastchanged_date": "April 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ramat-Gan", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "Liver Disease Center, Sheba Medical Center, Tel-Hashomer"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease in Diabetic Patients: Pre- and Post-Surgical Evaluation Utilizing Non-invasive Measures", 
        "overall_contact": {
            "email": "carmit.netanel@sheba.health.gov.il", 
            "last_name": "Carmit Netanel", 
            "phone": "+97235307185"
        }, 
        "overall_contact_backup": {
            "email": "avishag.hassid@sheba.health.gov.il", 
            "last_name": "Avishag Hassid", 
            "phone": "+97235307180"
        }, 
        "overall_official": {
            "affiliation": "Director Liver Disease Center, Sheba Medical Center, Tel-Hashomer, Israel", 
            "last_name": "Ziv Ben-Ari, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measurements to be performed to assess liver disease stage at baseline and at 8-12 days and 6, 12, 24 and 48 weeks after surgery:\nBlood tests of liver functions (Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase, gamma-glutamyl transpeptidase, ferritin, prothrombin-time (PT), international normalized ratio (INR), Total/Direct Bilirubin, Albumin, uric acid), lipids profile (total cholesterol, triglycerides, HDL, LDL) and diabetes biomarkers (insulin, glucose, HbA1c).\nBlood tests of adiponectin and tumor necrosis factor (only at baseline and at 12, 24 and 48 weeks after surgery).\nFibroscan test for quantifying liver fibrosis by means of elastography (only at baseline and at 24 and 48 weeks after surgery).\nA blood test (FibroMax) for determining the stage and grade of liver damage (only at baseline and at 12, 24 and 48 weeks after surgery).", 
            "measure": "Change from baseline liver steatosis, steatohepatitis and fibrosis at different stages after bariatric surgery, measured by non-invasive measurements as described below.", 
            "safety_issue": "No", 
            "time_frame": "Baseline is defined as three weeks to one month before surgery. Different stages to compare to baseline are as following: 8-12 days and 6, 12, 24 and 48 weeks after surgery."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A low carbohydrates diet will be given for 3 weeks to a month prior surgery  day.\nChange will be assessed by the following measurements 3 weeks to a month before surgery and at 1-2 days before surgery:\nBlood tests of liver functions (Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase, gamma-glutamyl transpeptidase, ferritin, PT, INR, Total/Direct Bilirubin, Albumin, uric acid), lipids profile (total cholesterol, triglycerides, HDL, LDL) and diabetes biomarkers (glucose, HbA1c).\nA blood test for determining the stage and grade of liver damage (FibroMax).\nAn intraoperative liver biopsy (on surgery day only).", 
                "measure": "Change of liver steatosis following a low carbohydrates diet at time of surgery compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "Baseline is defined as three weeks to one month before surgery. Change will be assessed 1-2 days before surgery."
            }, 
            {
                "description": "In addition, gastric cholecystokinin levels will be measured from the removed stomach tissue.", 
                "measure": "Change in cholecystokinin levels before and after the surgery.", 
                "safety_issue": "No", 
                "time_frame": "Baseline levels of cholecystokinin at 1-2 days before surgery compared to 8-12 days after surgery."
            }
        ], 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}